Royal Bank of Canada Reaffirms Outperform Rating for Addus HomeCare (NASDAQ:ADUS)

Addus HomeCare (NASDAQ:ADUS)‘s stock had its “outperform” rating reaffirmed by investment analysts at Royal Bank of Canada in a research note issued on Thursday,Benzinga reports. They presently have a $136.00 target price on the stock. Royal Bank of Canada’s price objective suggests a potential upside of 10.90% from the company’s current price.

ADUS has been the topic of several other reports. Macquarie reiterated an “outperform” rating and issued a $139.00 target price on shares of Addus HomeCare in a research note on Monday, November 4th. KeyCorp began coverage on shares of Addus HomeCare in a research note on Friday, October 11th. They issued an “overweight” rating and a $150.00 price objective on the stock. Stephens lifted their target price on shares of Addus HomeCare from $143.00 to $145.00 and gave the company an “overweight” rating in a report on Wednesday, November 6th. Oppenheimer lifted their price objective on Addus HomeCare from $140.00 to $145.00 and gave the company an “outperform” rating in a report on Monday, September 23rd. Finally, TD Cowen raised their price target on Addus HomeCare from $128.00 to $137.00 and gave the company a “buy” rating in a report on Thursday, August 8th. One analyst has rated the stock with a sell rating, eight have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $131.63.

Addus HomeCare Price Performance

Shares of ADUS traded down $0.66 during mid-day trading on Thursday, reaching $122.63. 12,337 shares of the company’s stock were exchanged, compared to its average volume of 131,230. The business’s fifty day simple moving average is $129.27 and its 200-day simple moving average is $122.06. The stock has a market capitalization of $2.22 billion, a PE ratio of 28.06, a price-to-earnings-growth ratio of 2.20 and a beta of 1.04. Addus HomeCare has a 52-week low of $85.43 and a 52-week high of $136.12.

Addus HomeCare (NASDAQ:ADUS) last posted its quarterly earnings data on Monday, November 4th. The company reported $1.30 EPS for the quarter, beating analysts’ consensus estimates of $1.28 by $0.02. Addus HomeCare had a net margin of 6.50% and a return on equity of 9.62%. The company had revenue of $289.80 million for the quarter, compared to analyst estimates of $289.42 million. During the same period in the previous year, the business posted $1.03 earnings per share. Addus HomeCare’s quarterly revenue was up 7.1% on a year-over-year basis. Equities research analysts predict that Addus HomeCare will post 4.58 earnings per share for the current year.

Insider Buying and Selling

In other Addus HomeCare news, EVP Michael D. Wattenbarger sold 21,917 shares of Addus HomeCare stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $133.29, for a total transaction of $2,921,316.93. Following the completion of the transaction, the executive vice president now owns 7,215 shares in the company, valued at approximately $961,687.35. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, EVP Michael D. Wattenbarger sold 21,917 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $133.29, for a total value of $2,921,316.93. Following the completion of the transaction, the executive vice president now directly owns 7,215 shares of the company’s stock, valued at $961,687.35. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Esteban Lopez sold 500 shares of Addus HomeCare stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $130.03, for a total value of $65,015.00. Following the sale, the director now owns 3,866 shares of the company’s stock, valued at approximately $502,695.98. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 22,917 shares of company stock worth $3,050,082 in the last three months. Corporate insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. BNP Paribas Financial Markets increased its stake in Addus HomeCare by 20.3% in the first quarter. BNP Paribas Financial Markets now owns 11,854 shares of the company’s stock valued at $1,225,000 after purchasing an additional 2,000 shares during the last quarter. Empowered Funds LLC boosted its position in shares of Addus HomeCare by 9.8% in the first quarter. Empowered Funds LLC now owns 6,890 shares of the company’s stock worth $712,000 after acquiring an additional 615 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in Addus HomeCare by 9.3% in the first quarter. Russell Investments Group Ltd. now owns 46,764 shares of the company’s stock valued at $4,833,000 after purchasing an additional 3,997 shares during the period. ProShare Advisors LLC raised its stake in Addus HomeCare by 7.3% during the first quarter. ProShare Advisors LLC now owns 3,163 shares of the company’s stock worth $327,000 after purchasing an additional 214 shares during the period. Finally, Entropy Technologies LP acquired a new position in shares of Addus HomeCare in the 1st quarter valued at $258,000. Hedge funds and other institutional investors own 95.35% of the company’s stock.

Addus HomeCare Company Profile

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. The company operates through three segments: Personal Care, Hospice, and Home Health.